Insiders' Blog
Sponsored by: Subscribe to EasyStockAlerts.com Now & Get The News Before Everyone Else!
Icahn Down $60M on Healthcare Stocks This Week (AMLN, BIIB, CYBX, REGN, FOLD)
So far this week, in only two days of trading, activist investor Carl Icahn has lost about $60 million in value on his positions in several healthcare companies:
- Biogen (Nasdaq: BIIB) - down 1% this week; this is one of Icahn's top 3 holdings and with over 17 million shares, he has lost about $10.5 million in value.
- Amylin Pharmaceuticals (Nasdaq: AMLN) - down 17% this week; the FDA issued a notice on Monday warning that Amylin's Byetta drug could be linked to severe pancreatitis. The stock plummeted and with about 6.78 million shares, Icahn is down about $41 million since yesterday.
- Cyberonics (Nasdaq: CYBX) - down 6% this week; the FDA announcement related to Amylin has hurt many other pharmaceutical companies. Icahn currently holds about 2.51 million shares and has lost about $4 million on his investment in Cyberonics this week.
- Regeneron Pharmaceuticals (Nasdaq: REGN) - down 5.8% this week; Icahn owns about 2.5 million shares, meaning he has lost about $3.3 million in just two days.
- Amicus Therapeutics (Nasdaq: FOLD) - down 17% this week; after nearly hitting a 52-week high last week, shares of Amicus have fallen five days in a row as insiders have recently been selling. Although Icahn only holds about 200,000 shares, this week's sharp decline has taken about $570,000 in value from Icahn compared to his holdings at last Friday's close.
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
